Angela Atinga MBBCHIR, BA, Presenter: Nothing to Disclose

Yaron J. Berkowitz MBBChir, MRCS, Abstract Co-Author: Nothing to Disclose

Andrea Grace Rockall MRCP, FRCR, Abstract Co-Author: Nothing to Disclose

Nishat Bharwani MBBS, FRCR, Abstract Co-Author: Nothing to Disclose

Victoria Stewart, Abstract Co-Author: Nothing to Disclose

- Revise the CT findings in ovarian cancer and the role of surgery in management of patients - Identify the expected postoperative CT findings following ovarian cancer cytoreductive/debulking surgery - Differentiate between expected changes and those that may represent complications or residual disease. - Highlight areas that require particular attention during interpretation

There is a well-established role for cytoreductive or debulking surgery in the management of both early and advanced ovarian cancer, and surgical targets are often imaging led. Surgery may be performed before or after chemotherapy in the first instance, in managing recurrent disease, or palliatively. CT imaging is often performed post operatively. One of the difficulties is identifying and differentiating between expected post-operative changes, surgical complications and residual disease.  Our table of contents will be: - Common CT findings in ovarian cancer - Debulking surgery and expected findings in post-operative imaging - Pictorial review of surgical complications and residual disease that may mimic post-surgical change - A useful ‘tips & tricks’ checklist to help distinguish between expected post-operative changes, surgical complications and residual disease  

http://abstract.rsna.org/uploads/2014/14014753/14014753_b236.pdf

Atinga, A, Berkowitz, Y, Rockall, A, Bharwani, N, Stewart, V, Differentiating Residual Disease in Postoperative Ovarian Cancer.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14014753.html